Fox Chase Cancer Center | Strategic Alliance Partners

February 02, 2022

Angela Jain, MD, provides perspective on use of PARP inhibitors in the treatment of patients with advanced ovarian cancer.

December 05, 2021

Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.

November 25, 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what the benefits are of an oncology fellowship and the takeaways and important lessons Nardello learned from his own breast oncology fellowship at Fox Chase Cancer Center.

November 25, 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what brought Dr. Nardello to the breast cancer field, what made him decide to pursue an oncology fellowship, and what residents should think about when choosing a fellowship location.

November 10, 2021

The 9th Annual Giants of Cancer Care® awards ceremony was a featured event at the 39th Annual CFS®: Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow®, hosted by Physicians’ Education Resource® LLC.

October 22, 2021

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

October 08, 2021

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

October 05, 2021

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

August 30, 2021

Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, was recently awarded a Specialized Program of Research Excellence grant of $50,000 for a pilot project examining differences in risk and disease course for Black versus white head and neck cancer patients.

July 27, 2021

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

June 25, 2021

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

May 21, 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

May 21, 2021

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

May 17, 2021

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.

May 14, 2021

Eric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.

March 24, 2021

Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.

March 20, 2021

Key updates to the National Comprehensive Cancer Network guidelines for gastric and esophageal cancers include the incorporation of immune checkpoint inhibitors spanning settings in patients with gastroesophageal cancer, the inclusion of fam-trastuzumab deruxtecan-nxki for those with HER2-positive gastric cancer, and the addition of recommended ramucirumab combinations for use in second- or later-line settings.

March 03, 2021

Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.

December 17, 2020

In our exclusive interview, Dr. Borghaei and Dr. Gunuganti discuss patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike.

November 05, 2020

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.